Manufacturer: Amylin Pharmaceuticals, San Diego, Calif. Indication: Bydureon, administered once weekly as a subcutaneous (SQ) injection, is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type-2 diabetes mellitus. Drug Class: Exenatide is a synthetic hormone and an incretin mimetic derived from the saliva of the Gila monster, a poisonous lizard in the southwestern U.S. and Mexico. Uniqueness of Drug: As a glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide mimics the effect of glucagon-like peptide-1, a hormone that increases insulin production when blood glucose levels are high. Insulin is slowly released in the body after injection. Byetta (Amylin/Eli Lilly), which is injected twice daily, was the first GLP-1 receptor agonist to be approved by the FDA for patients with type-2 diabetes mellitus. Bydureon is a long-acting form of the medication in Byetta (exenatide) injection; therefore, both drugs should not be used together.
展开▼
机译：生产商：Amylin Pharmaceuticals，加利福尼亚州圣地亚哥。适应症：Bydureon每周一次皮下注射（SQ）注射，被认为是饮食和锻炼的辅助手段，可改善成年2型糖尿病患者的血糖控制。药物类别：艾塞那肽是一种合成激素，是一种由美国西南部和墨西哥的有毒蜥蜴吉拉怪物的唾液所产生的肠降血糖素模拟物。药物的独特性：艾塞那肽作为一种胰高血糖素样肽1（GLP-1）受体激动剂，模仿了胰高血糖素样肽1的作用，胰高血糖素样肽1在血糖水平高时会增加胰岛素的产生。注射后，胰岛素在体内缓慢释放。每天注射两次的Byetta（Amylin / Eli Lilly）是FDA批准用于2型糖尿病患者的首个GLP-1受体激动剂。 Bydureon是Byetta（艾塞那肽）注射液中的一种长效药物。因此，两种药物不应同时使用。
展开▼
